MOLSON COORS BEVERAGE CO (TAP): what the price requires

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/TAP

Headline

Field	Value
Ticker	TAP
Company	MOLSON COORS BEVERAGE CO
Sector / Industry	Consumer Defensive
Current price	$39.67/sh
Composition	United States and its territories 66% / Canada 11% / United Kingdom 13% / Other countries 10%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Field	Value
Inversion basis	whole-company
Operating margin needed	8.2%
Operating margin (mid-cycle)	13.2%
Margin compression implied	-5.0pp
Trailing margin (depressed year)	-16.3%
Multiple paid	9x mid-cycle operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage (computed at the 7% minimum rate; the CAPM rate 5.1% sits below it).

How unusual the bet is: within-range (limited comparison data)

Reference	Value
vs own history	+0.15σ
implied end-window share	0%

Valuation X-Ray

The price is supported by asset-based and relative-multiple value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Family	Median price/FV	Models	Reads
Asset	0.85x	3	justifies
Earnings	1.41x	2	expensive
Relative	0.30x	3	justifies
Growth	1.31x	4	expensive

Families that justify the price: Asset, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 4.6%); the inversion above states its own rate.

Per-Model Detail (n=12)

Model	Family	FV	Price/FV	Applicable	Methodology
DCF Perpetual Growth	Growth	$67.11	0.59x	yes	FCF base $1.1B, growth -5% (input: historical growth), terminal g 0.5%, WACC 4.6%, 5yr projection
DCF Exit Multiple	Growth	$53.01	0.75x	yes	Exit EV/EBITDA: 5.3x / 7.3x / 9.3x (bear / base = today's held flat / bull), 5yr
Relative Valuation	Relative	$131.79	0.30x	yes	P/S fallback (negative EPS): Sector P/S 2.0x × TTM revenue — excluded from consensus
Simple DDM	Growth	$4.80	8.26x	yes	DPS $1.83, g=-20.9% (sustainable: ROE (TTM) × retention; not the terminal-growth assumption), ke=9.3%
Two-Stage DDM	Growth	$-22.62	—	no	Stage 1: -200% for 5yr, Stage 2: 3.5% perpetual
Simple Excess Return	Asset	$51.69	0.77x	yes	Reference only (book value floor): BV/sh $51.69, ROE negative
Two-Stage Excess Return	Asset	$46.52	0.85x	yes	Reference only (book value with convergence): BV/sh $51.69, ROE converges to ke
Discounted Future Market Cap	Growth	$21.10	1.88x	yes	Rev $13.0B, growth -5% (input: historical growth; tapered), Terminal P/S: 0.5x / 0.6x / 0.7x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair Value	Relative	$0.00	—	no	Negative/zero EPS — earnings-based value floored at $0
Margin Trajectory	Growth	—	—	no	—
Earnings Power Value	Earnings	$65.63	0.60x	yes	Normalized EBIT (5y avg op income, one-time charges added back) $1.24B × (1−21%) / WACC 4.6% → EPV (no growth)
Residual Income	Asset	—	—	no	—
Graham Number	Asset	—	—	no	—
EV/EBITDA Relative	Relative	$112.86	0.35x	yes	EBITDA $2.17B × sector EV/EBITDA 14.0x
FCF Yield	Earnings	$17.85	2.22x	yes	FCF $1067.8M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF Yield	Earnings	—	—	no	—
Ben Graham Formula	Earnings	—	—	no	—
ROIC-Justified P/B	Asset	$15.62	2.54x	yes	BV $51.69 × (ROIC 1.4% / WACC 4.6%)
P/Sales Sector	Relative	$131.79	0.30x	yes	Revenue $13.04B × sector P/S 2.0x
PEG Fair Value	Relative	—	—	no	—
Earnings Yield	Earnings	—	—	no	—
Funds From Operations Multiple	Relative	—	—	no	—
Clinical Phase NPV	Growth	—	—	no	—
Merton	Asset	—	—	no	—
V5 Mechanical	—	—	—	no	—

Solvency

Field	Value
Net debt	$7.9b
Net debt / NOPAT (after-tax)	5.60x
Net debt / operating income (pre-tax)	4.40x
Interest coverage	6.1x
Share count CAGR (buyback)	-2.3%
Burning cash	no

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 13.2%); the trailing year was depressed.

Bullet Takeaways

• Molson Coors trades at about 9 times through-cycle operating income and 0.76 times book value, a price below what even a permanent 5% annual profit decline would warrant, while premiumization lifted net sales per hectoliter 9.3% in FY2025 [FY2025 10-K, accession 0000024545-26-000006].

• The biggest risk is that the discount is deserved: the $3.87 billion impairment was triggered by beer-industry decline and market share losses, the filing flags the Americas unit (78% of net sales) as still at heightened risk of further impairment, and FY2026 guidance points to a double-digit decline in adjusted earnings.

• Watch quarterly U.S. volume and share trends against the industry's roughly 4.7% decline, execution on the three-year $450 million cost-savings program, and whether the $1.83 dividend plus 2.3% annual share-count shrink stays fully funded by free cash flow.

Bull Case

One number does most of the work here: at $39.17 the market is paying about 9 times Molson Coors' through-cycle operating income, a multiple low enough that the price sits below what even a 5% annual decline in operating profit, sustained indefinitely, would warrant. That is the entire bull case in a sentence. The buyer at today's price does not need beer to grow; the buyer needs beer to shrink more slowly than a rout, and everything the company does right from here, cost cuts, premiumization, buybacks, is upside against a bar set below zero.

The operating evidence says the business is managing its decline rather than being managed by it. The 10-K attributes a 4.5% lift to net sales primarily due to premiumization, geographic mix and higher factored brand volume, as well as increased net pricing, with net sales per hectoliter up 9.3% [FY2025 10-K, accession 0000024545-26-000006], which is the pattern of a company successfully charging more per liter as it sells fewer liters. The strategy language is explicit about the pivot: investments to strengthen our core and value beer portfolios and to transform our above premium beer and beyond beer portfolios [FY2025 10-K, accession 0000024545-26-000006]. The first quarter of 2026 showed the arithmetic working, with basic EPS from continuing operations rising to $0.80, up 24%, even as volumes fell, helped by Peroni growing volumes 25%, and management layered on a three-year $450 million cost-savings program.

Meanwhile the shareholder is paid twice while waiting. The dividend runs at $1.83 per share, roughly a 4.7% yield at today's price, and the share count has fallen about 2.3% a year over the past four years, so per-share claims on a stable cash stream keep rising mechanically. The company generated about $1.1 billion of trailing free cash flow against a $7.75 billion market capitalization and is not burning cash despite the headline accounting loss, which was a non-cash impairment, not an operating event. A declining business priced for faster decline than it is exhibiting, returning double-digit percent of its market cap to holders annually between the dividend and the buyback, is a value setup that does not require optimism, only the absence of catastrophe.

Bear Case

Americans are drinking less beer, and within that shrinking pool, Molson Coors is losing share. That is not a bear's caricature; it is the company's own accounting confession. The 10-K explains the $3.87 billion impairment's trigger as lower current year and future forecasted results which were driven by declines in the beer industry, market share losses, and adds that the Americas reporting unit is still considered to be at a heightened risk of future impairment [FY2025 10-K, accession 0000024545-26-000006]. When management writes down its own goodwill and then warns the write-down may not be finished, the cheap-looking multiple is not a market error. It is the market reading the same disclosure.

Concentration makes the industry problem a company problem. The filing notes that net sales in our Americas segment accounted for approximately 78% of our total 2025 net sales and frames the dependence directly: to the extent the company cannot maintain or grow share in mature markets, sales and the business follow [FY2025 10-K, accession 0000024545-26-000006]. The U.S. beer market declined 4.7% in the recent period, and consolidated net sales fell 3.3% with underlying pretax income down 11.9% around the impairment. Peroni growing 25% is a genuine bright spot, but it is a small brand's growth set against the erosion of Coors Light and Miller Lite volumes that pay the bills. Premiumization raises revenue per hectoliter; it does not manufacture new beer drinkers.

The financial structure leaves less margin for error than the defensive label suggests. Net debt stands at $7.86 billion, roughly 4.6 times through-cycle operating income, against only about $900 million of liquid assets. The dividend and buyback that anchor the bull case consumed most of the roughly $1.1 billion of trailing free cash flow, so the shareholder-return program depends on cash generation not eroding alongside volumes. And the forward guidance concedes the direction: full-year 2026 points to a double-digit decline in adjusted earnings. A company priced below book value, with its largest region running at a loss after impairments and its own filing flagging more impairment risk, is cheap the way declining franchises are usually cheap: for stated reasons.

Valuation

The price is best understood as a bound rather than a bet. At $39.17 (July 10, 2026), Molson Coors trades at roughly 9 times its own through-cycle operating income, low enough that the price sits below what even a sustained 5% annual decline in operating profit would justify. The market is not asking what the company must achieve; it is asserting the company will do worse than a steady, permanent shrink. The company's near-term operating pace sits within what it has recently delivered, so the question the price poses is entirely about how long the decline runs, not whether the current rate is survivable.

Two earnings bases coexist here and need naming once. The trailing statutory figure shows an operating loss of roughly $2.3 billion, dominated by the $3.87 billion non-cash impairment of the Americas unit; the through-cycle basis, using the company's own normal margins of about 13% on current revenue, puts operating income near $1.7 billion. Every valuation lens picks a side. Sector-multiple comparisons read the stock as drastically cheap, with the price at roughly a third of what sector-median sales and EBITDA multiples would support on $13.0 billion of trailing revenue; book-value reads sit modestly above the price, with $51.69 of book value per share against a $39.17 share price. The forward cash-flow lenses are more cautious, reflecting negative historical growth, and a dividend-growth read is essentially inapplicable while reported earnings are impairment-depressed. The pattern is a value read: the static and multiple-based methods support the price with room to spare, and nothing in the disagreement requires believing in growth.

The balance sheet can sustain the wait if operations hold. Net debt of $7.86 billion runs about 4.6 times through-cycle operating income with interest coverage around 7 times on the same basis, liquid assets are about $900 million, and free cash flow of roughly $1.1 billion funds the $1.83 dividend and a buyback that has shrunk the share count 2.3% a year for four years. Geography is the watch item inside the blend: the Americas carry 78% of revenue and absorbed the impairment, while the EMEA and APAC business runs near breakeven [FY2025 10-K, accession 0000024545-26-000006]. What the price requires is modest to the point of pessimism; what the filing flags, heightened risk of further Americas impairment, is the specific way the pessimism could still win.

Catalysts

The next quarterly print is the main event, and it carries a specific tension: first-quarter 2026 delivered basic EPS from continuing operations of $0.80, up 24%, on rising net income of $151.3 million, yet full-year guidance still points toward a double-digit decline in adjusted earnings. Either the quarterly momentum forces a guidance raise or the back half deteriorates as guided; the second-quarter report, on the company's usual early-August cadence, starts resolving which.

The cost program supplies the self-help calendar. Management announced a three-year $450 million cost-savings initiative alongside the stronger first quarter, and early proof points, plant consolidation, procurement savings, overhead reduction, would land directly on a stock priced below a permanent-decline scenario. Volume trends frame the other side: the U.S. beer market fell about 4.7% in the recent period, and each quarter's shipment and share data tests whether Molson Coors is holding its ground inside the decline. Peroni's 25% volume growth is the premiumization proof point to track for durability.

The accounting overhang is worth a date on the calendar too. The FY2025 filing recorded a $3.87 billion partial impairment of the Americas unit and stated the unit remains at heightened risk of further impairment, an assessment revisited at least annually and upon triggering events. A second write-down would be non-cash but would reset the book-value anchor under the stock, while a year of stabilized results would retire the risk factor. Dividend declarations, running at $1.83 per share annualized, and the pace of buyback execution round out the shareholder-return items to watch through year-end.

Peer Cohorts (Per Segment, With Filing Citations)

EMEA&APAC (reported)

• SAM (THE BOSTON BEER COMPANY, INC.)
• (no filing in the citation store)
• BUD (Anheuser-Busch InBev SA/NV)
• (no filing in the citation store)
• STZ (CONSTELLATION BRANDS, INC.)
• (no filing in the citation store)
• ABEV (AMBEV S.A.)
• (no filing in the citation store)

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Molson Coors Q1 2026 results, May 2026 · Molson Coors results coverage, 2026 · Molson Coors guidance coverage, 2026 · Molson Coors Q1 2026 results and guidance coverage, 2026 · Molson Coors Q1 2026 coverage, 2026